Expert Advice 8 May 2019 Why It’s Important to “Think Big” When Raising Money for Your Company There are not many people who can say they led one of Europe’s largest biotechs and launched the first approved gene therapy in Europe. Joern Aldag, now CEO at Austrian biotech Hookipa Pharma, has done both. Aldag got into biotech because he wanted to use his entrepreneurial skills to advance medicine. After 9 years of […] May 8, 2019 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2019 Hookipa’s €75M IPO to Fund Vaccines for Viral Infection and Cancer The Austrian biotech Hookipa expects to raise €75M ($84M) in an IPO on the Nasdaq stock exchange to fund the phase II development of a vaccine for the virus cytomegalovirus, and the first clinical trials of its cancer vaccines. Based in Vienna, Hookipa develops vaccines based on engineered viruses called arenavirus. The company programs arenaviruses […] April 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2019 Austrian Biotech Raises €33.2M to Fund Cancer Vaccines A Series D round of €33.2M ($37.4M) is to help the biotech Hookipa advance the clinical development of therapeutic vaccines for virus-based cancers, as well as a prophylactic vaccine for cytomegalovirus, which can infect patients undergoing organ transplants. Currently at the preclinical stage, Hookipa’s therapeutic vaccines are designed to tackle cancers that are caused […] February 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2019 Austrian Biopharma Reaches First HIV Vaccine Milestone Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […] January 3, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 7 Feb 2018 Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress Did you miss us in Vienna? Here’s the first of our two interviews from the Refresh meetup last month: Jörn Aldag, CEO of Hookipa, talked to us about the importance of a sound financial strategy and where cancer vaccines are on the hype curve. Jörn Aldag has had quite a career. His first position as […] February 7, 2018 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech Gilead has joined a growing list of powerful investors that want to help Hookipa Biotech develop its vaccine technology by participating in its Series C fundraising. Hookipa Biotech, one of October’s biotechs of the week, develops vaccines for cancer and infectious diseases. Its pipeline includes two platforms: Vaxwave and TheraT, which are targeted at cytomegalovirus infections and […] December 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2017 Solid First-in-Human Results from Vaccine against Birth Defects Hookipa has presented positive data from its first Phase I trial testing its vaccine technology against human cytomegalovirus (hCMV) infections. Hookipa, one of the top 10 biotechs we’re closely following this year, is developing a viral vaccine platform that has attracted big investments from both the private and the public sector. The company just announced […] May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 €4M Grant for a Cancer Vaccine that could Bench its Competitors Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […] October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email